Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 2Thoracic 1Gynecologic 1Dermatologic 1

Conditions

Stomach Neoplasms 20Carcinoma, Non-Small-Cell Lung 18Neoplasms 10Adenocarcinoma 8Neoplasm Metastasis 7Colorectal Neoplasms 7Carcinoma, Hepatocellular 6Esophageal Neoplasms 5Carcinoma, Renal Cell 5Breast Neoplasms 5Colonic Neoplasms 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Melanoma 3Liver Neoplasms 3Biliary Tract Neoplasms 3Ureteral Neoplasms 2Solid Tumors 2Sarcoma 2Rectal Neoplasms 2Ovarian Neoplasms 2Non-small Cell Lung Cancer Metastatic 2Malignant Solid Tumor 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Transitional Cell 2Solid Tumor 1Solid Cancer 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1

Interventions

pembrolizumab 40Gemcitabine 37Cisplatin 28Carboplatin 17enfortumab vedotin 15Nivolumab 15Mitomycin 14atezolizumab 13avelumab 12Docetaxel 10vinflunine 95-aminolevulinic acid hexyl ester 9apaziquone 8Paclitaxel 8BCG Vaccine 7durvalumab 6Fluorouracil 6Cystectomy 6sacituzumab govitecan 4Surgical Procedures, Operative 4Drug Therapy 4vofatamab 3valrubicin 3tisotumab vedotin 3erdafitinib 3cemiplimab 3belinostat 3Therapeutic Uses 3Ramucirumab 3Cystoscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Urinary Bladder Neoplasms × Ramucirumab × Clear all
NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Toray Industries, Inc

Phase 1 Active not recruiting
138 enrolled
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02443324 2024-07-31

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Eli Lilly and Company

Phase 1 Completed
175 enrolled 23 charts
GastrointestinalGenitourinaryThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT02426125 2023-08-21

RANGE

Eli Lilly and Company

Phase 3 Completed
530 enrolled 22 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡